جست‌وجوی استاد و پژوهشگر

Kristian Helinمشاهده پروفایل

استاد

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

Paul Stuppleمشاهده پروفایل

استاد

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +۳ مورد دیگر

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

• Pharmacology
• Traditional Chinese Medicine
• Cancer Therapy
• +۷ مورد دیگر

Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.

Ahmet Acarمشاهده پروفایل

دانشیار

• Cancer Biology
• Precision Medicine
• Drug Resistance Mechanisms
• +۳ مورد دیگر

Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.

David S. Eisenbergمشاهده پروفایل

استاد

• Protein Aggregation
• Amyloid Structures
• Prion Diseases
• +۵ مورد دیگر

David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.

• Cancer Targeting
• Drug Design
• Drug Delivery
• +۴ مورد دیگر

About Dr. Pegah Varamini Dr. Pegah Varamini is a Senior Lecturer in Pharmacy and Pharmacology at the Sydney Pharmacy School, University of Sydney, and a Casual Lecturer in Music Education at the Sydney Conservatorium of Music. She leads the Breast Cancer Targeting & Drug Delivery (BCTDD) Group, focusing on innovative drug delivery systems for Triple Negative Breast Cancer (TNBC). Her research integrates nanotechnology, targeted therapy, and translational medicine, supported by prestigious grants including the NBCF Fellowship (2016). Research & Education PharmD (Shiraz University of Medical Sciences) PhD in Pharmaceutical Sciences (University of Queensland) Second PhD in Music Education (University of Sydney Conservatorium of Music) Key Research Interests Her work centers on: Peptide-based targeting strategies using 'Trojan Horse' approaches for TNBC Development of nanomedicine for bone metastasis prevention Clinically relevant preclinical models for personalized breast cancer treatment Collaborations with international institutions (e.g., Harvard Medical School, University of Nantes) Teaching & Supervision Dr. Varamini coordinates Drug Design and Development (PCOL3012/3912) and supervises a multidisciplinary team of HDR students and postdoctoral researchers. Notable current students include PhD candidate Hany Ghaly and MPhil candidates Huimin Shao and Farhana Mollah. Awards & Recognition 2021 Equity Prize 2016 Top 25 Young Researchers of Australia and New Zealand 2018 Fresh Scientist of the Year Recipient of multiple grants totaling over AUD 2M Leadership & Outreach She co-chairs the Nanopharma cluster at Sydney Nano Institute and advises the WHO Global Breast Cancer Initiative. Her work has been featured in media outlets such as SBS Farsi News and NBCF publications.

• Cardiovascular Disease
• Biomedical Engineering
• Thrombosis Prevention
• +۵ مورد دیگر

Associate Professor Anna Waterhouse is a Robinson Fellow and Head of the Cardiovascular Medical Devices Group at the Charles Perkins Centre, School of Medical Sciences, University of Sydney. Her research focuses on developing antithrombogenic materials and bioinspired medical devices to address cardiovascular diseases. She holds affiliations with the University of Sydney Nano Institute and the Australiasian Society for Biomaterials and Tissue Engineering as Treasurer and Secretary. Education includes a BSc (1st class hons) in Cell Biology from the University of Manchester and a PhD in bioengineering from the University of Sydney. She completed postdoctoral training at Harvard University’s Wyss Institute. Research interests span biomaterials, thrombosis prevention, and medical device engineering. Key projects include liquid-infused surfaces for anti-thrombotic coatings and biomimetic in vitro models. Her work integrates bioengineering, nanotechnology, and surface modification to improve medical device compatibility. Scientific awards include the Robinson Fellowship and CPC Mid-Career Researcher Support Award. Grants funded by ARC, Heart Foundation, and NSW Health support projects like slippery nano-coatings for medical devices. She advises PhD students in biomolecular nanotechnology, endothelial cell studies, and DNA nanostructures. Labs and collaborations involve Sydney Nano Institute and Charles Perkins Centre, focusing on translational research in cardiovascular and biomedical engineering.

• Nuclear Magnetic Resonance (NMR)
• In vivo imaging
• MRI pulse sequence development
• +۷ مورد دیگر

Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۱۲ مورد دیگر

Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.

John A. Copland, IIIمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Carcinogenesis
• Translational Research
• +۳ مورد دیگر

Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models

Christopher E. Nelsonمشاهده پروفایل

استادیار

• Gene therapy
• Regenerative medicine
• Genome editing
• +۷ مورد دیگر

Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.

Laura Soltمشاهده پروفایل

دانشیار

• Autoimmune Disease
• Cancer Immunotherapy
• Immunometabolism
• +۵ مورد دیگر

Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.

Paula Gonzalez-Figueroaمشاهده پروفایل

پژوهشگر ارشد

• Immunology
• Autoimmunity
• Allergy
• +۶ مورد دیگر

Dr. Paula Gonzalez-Figueroa is a Research Fellow at the Clinical Hub for Interventional Research (CHOIR) in the College of Health and Medicine at The Australian National University (ANU). She holds a PhD in Medical Sciences from ANU and completed postdoctoral research at the John Curtin School of Medical Research (ANU) and the Francis Crick Institute (UK). Her research focuses on immunology, autoimmunity, allergy, and clinical translation. Education: PhD in Medical Sciences (ANU), Biotechnology degree. Research Interests: Regulatory T cells, germinal centers, B cell biology, neuritin-based therapies, preclinical drug testing, and early-phase clinical trials. Affiliations: CHOIR (Researcher), Polizzotto Group, Genome Sciences and Cancer Division. Her work includes developing a neuritin-based biotherapeutic for allergies and autoimmune diseases, and leading preclinical/Phase I clinical programs for hematological cancers. She has contributed to studies on Tfr cell regulation, IgE responses, and germinal center dynamics. Publications span immunology, molecular biology, and translational research, with notable contributions to Nature Immunology , Cell , and Journal of Experimental Medicine .

Li Tangمشاهده پروفایل

دانشیار

• Immunoengineering
• Cancer Immunotherapy
• Immune Metabolism
• +۷ مورد دیگر

Li Tang is an Associate Professor with tenure at École polytechnique fédérale de Lausanne (EPFL), affiliated with the Institute of Bioengineering (IBI) and the Institute of Materials Science and Engineering (IMX) within the School of Engineering (STI). She leads the Laboratory of Biomaterials for Immunoengineering, focusing on developing innovative strategies at the intersection of immunology, materials science, and cancer therapy. Her work bridges fundamental research and clinical translation, with multiple ongoing clinical trials based on CAR-T cell therapies developed in her lab. B.S. in Chemistry, Peking University (2003–2007) Ph.D. in Materials Science and Engineering, University of Illinois at Urbana-Champaign (2007–2012) Postdoctoral Fellow, MIT (2013–2016) Her research lies at the forefront of immunoengineering, integrating chemical, metabolic, and mechanical approaches to modulate immune responses. Key areas include cancer immunotherapy, immune metabolism, mechano-immunology, and biomaterials. She investigates how physical and biochemical cues can reprogram T cells, overcome exhaustion, and enhance tumor targeting. Her work emphasizes multidimensional immunity-disease interactions, aiming to develop safer and more effective therapies for cancer and autoimmune diseases. The recent publications highlight a strong trend in engineering immune cells (especially CAR-T) for enhanced durability and function, using advanced biomaterials and metabolic reprogramming. There is a clear focus on overcoming challenges in solid tumors, modulating the tumor microenvironment, and translating findings into clinical applications. The use of nanoparticle delivery, single-cell analysis, and biomechanical cues are recurring themes across her work. Notable scientific awards include: Friedrich Miescher Award (2025) ERC Starting Grant (2018) MIT TR35 Innovators Under 35 (China Region, 2020) Nano Research Young Innovator Award (2018) Biomaterials Science Emerging Investigator (2019) Materials Horizons Emerging Investigator (2020) Li Tang actively mentors PhD students across multiple doctoral programs (EDBB, EDMS, EDMX) and has advised numerous graduates who have gone on to prestigious postdoctoral and faculty positions. She is involved in significant research grants, including an Innosuisse project with Novochizol SA, and her lab is supported by competitive funding. She teaches core courses such as Immunoengineering and Next-Generation Biomaterials, shaping the next generation of scientists. Her lab fosters interdisciplinary collaboration and innovation, with active projects in chemical, metabolic, and mechanical immunoengineering, as well as CAR-T cell development. She is the Principal Investigator of the Tang Lab, which includes postdoctoral fellows, PhD students, and technical staff. The lab is actively recruiting and has a strong publication and clinical translation record. Tang Lab is also involved in multiple MA/BA training projects and promotes student engagement in cutting-edge research. The lab’s discoveries are being translated into clinical trials, reflecting a strong commitment to translational science.

Istvan Modyمشاهده پروفایل

استاد

• Neuroscience
• Neurology
• Pharmacology
• +۱۲ مورد دیگر

Istvan Mody is a Professor at the University of California, Los Angeles (UCLA) with appointments in the Department of Neurology and Department of Physiology . His research focuses on synaptic signaling in health and disease, including mechanisms of GABAergic transmission, calcium homeostasis, and their roles in neurological disorders such as epilepsy, Alzheimer's disease, Huntington's disease, stress, alcoholism, and postpartum depression. He utilizes advanced techniques like patch-clamp electrophysiology, neuroanatomical and immunohistochemical methods, and molecular biology in animal models and human brain tissue . Research Interests: Dr. Mody investigates the physiology, pharmacology, and pathology of synaptic transmission and extrasynaptic receptor activation , with a particular emphasis on GABA(A) receptors and their subunit-specific modulation. His work explores how disruptions in excitation-inhibition balance contribute to neurological diseases, including mechanisms of tonic inhibition , calcium signaling , and neurosteroid interactions . He also studies the effects of chronic stress and hormonal fluctuations on neural excitability and behavior. Publications Trends: Recent studies highlight his work on gamma oscillations in Alzheimer's models, microglial dynamics , and rehabilitation strategies for stroke. His lab develops optical tools like dqGEVI for neuronal activity monitoring and investigates human brain organoids to model network dysfunction in epilepsy and intellectual disability. Laboratory Location: 635 Charles Young Dr S, Los Angeles, CA 90095, United States.